Ticagrelor Ticagrelor Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y receptor. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high
Phosphoric acid Phosphoric acid Phosphoric acid (also known as orthophosphoric acid or phosphoric(V) acid) is a weak acid with the chemical formula HPO. Orthophosphoric acid refers to "phosphoric acid", which is the IUPAC name for this compound. The prefix "ortho-" is used to distinguish the acid from related phosphoric acids, called polyphosphoric acids. Orthophosphoric acid is a non-toxic acid, which, when pure, is a solid at room temperature and pressure. The conjugate base of phosphoric acid is the dihydrogen phosphate ion, , which in turn has a conjugate base of hydrogen phosphate, , which has a conjugate base of phosphate, . Phosphates